肿瘤负荷与位置对局限前列腺癌碘粒子植入近距离治疗预后的影响
该研究纳入282例接受永久性碘粒子植入近距离治疗的局限前列腺癌患者,分析阳性活检针百分比及肿瘤位置与无进展生存的关系。中位随访64个月,7%患者进展,5年控制率93%;阳性针百分比和肿瘤位置均与无进展生存无显著关联,进展者中Gleason评分≥7更常见。
要点
- 阳性活检针百分比和肿瘤位置与无进展生存无显著关联。
- 进展患者中Gleason评分≥7的比例显著更高(40% vs 19%,p=0.042)。
- 严格筛选患者后近距离治疗5年控制率达93%。
核心结论
- 在经典标准严格筛选的局限前列腺癌患者中,碘粒子植入近距离治疗5年控制率为93%。
- 阳性活检针百分比和肿瘤位置与无进展生存无显著关联。
- 进展患者中Gleason评分≥7更常见(40% vs 19%,p=0.042)。
研究设计与样本
- 单中心回顾性研究,2006至2013年共382例接受永久性碘粒子植入近距离治疗的局限前列腺癌患者,282例纳入分析。
- 纳入条件为有详细病理报告且最低随访6个月。
- 进展定义包括生化、局部、淋巴结或远处转移复发。
主要发现
- 197例(69.9%)为低危,67例(23.8%)为有利中危,16例(5.7%)为不利中危,1例(0.3%)为高危。
- 中位阳性活检针百分比为17%[3-75%],中位随访64个月[12-140]。
- 20例(7%)进展:4例(20%)仅生化进展,7例(35%)前列腺或精囊进展,6例(30%)淋巴结进展,3例(15%)转移。
- 中位失败时间39.5个月[9-108]。
- 所有研究协变量(包括肿瘤位置和阳性活检针百分比)均与无进展生存无显著关联,风险分组呈关联趋势(p=0.055)。
临床怎么用
- 对于经典标准筛选的局限前列腺癌患者,碘粒子植入近距离治疗可获得高5年控制率。
- 阳性活检针百分比和肿瘤位置不应单独作为排除近距离治疗的标准。
- Gleason评分≥7与进展风险相关,选择患者时需关注。
局限性
- 回顾性单中心研究,部分患者因病理报告不可及或随访不足被排除。
- 进展事件数较少(20例),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iodine seed implant brachytherapy is indicated for low risk and selected favorable intermediate risk prostate cancers. A percentage of positive biopsies > 50% is usually considered as a contra-indication, and the tumor location could also influence the treatment efficacy. We studied the association of the percentage of positive biopsy cores, and tumor location, with progression-free survival. METHODS: Among the 382 patients treated at our center by permanent implant iodine seed brachytherapy for a localized prostate cancer between 2006 and 2013, 282 had accessible detailed pathology reports, a minimum follow-up of 6 months, and were included. Progression was defined as a biochemical, local, nodal, or distant metastatic relapse. We studied cancer location on biopsies (base, midgland or apex of the prostate) and percentage of positive biopsy cores, as well as potential confounders (pre-treatment PSA, tumor stage, Gleason score, risk group according to D'Amico's classification modified by Zumsteg, adjunction of androgen deprivation therapy, and dosimetric data). RESULTS: Most patients (197; 69.9%) had a low risk, 67 (23.8%) a favorable intermediate risk, 16 (5.7%) an unfavorable intermediate risk, and 1 (0.3%) a high-risk prostate cancer. An involvement of the apex was found for 131 patients (46,5%), of the midgland for 149 (52,8%), and of the base for 145 (51,4%). The median percentage of positive biopsy cores was 17% [3-75%]. The median follow-up was 64 months [12-140]. Twenty patients (7%) progressed: 4 progressions (20%) were biochemical only, 7 (35%) were prostatic or seminal, 6 (30%) were nodal, and 3 (15%) were metastatic. The median time to failure was 39.5 months [9-108]. There were more Gleason scores ≥7 among patients who progressed (40% vs 19%; p = 0.042). None of the studied covariates (including tumor location, and percentage of positive biopsy cores), were significantly associated with progression-free survival. The risk group showed a trend towards an association (p = 0.055). CONCLUSIONS: Brachytherapy is an efficient treatment (5-year control rate of 93%) for patients carefully selected with classical criteria. The percentage and location of positive biopsies were not significantly associated with progression-free survival. A Gleason score ≥ 7 was more frequent in case of progression.
引用
- Meynard C, Huertas A, Dariane C, et al. Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers. Radiat Oncol. 2019. PMID: 31892338. doi:10.1186/s13014-019-1449-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。